TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01704040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3157 (healthy participants)
Description: CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (healthy participants)
Description: Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 3157 (asthmatic patients)
Description: CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (asthmatic patients)
Description: Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-16
Description: Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HRV-16
Description: Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-16
Description: Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HRV-16
Description: Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
Study: NCT02712476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mannitol
Description: This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: This drug is can be used alone or with mannitol for brain relaxation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: mannitol alone is compared with placebo
Study: NCT03614754

Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory evoked potentials
Description: Stimulation of the pudendal nerve while recording at the sensory cortex.
Study: NCT00188344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic myotomy with partial fundoplication
Description: The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
Study: NCT01709084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
Study: NCT01987687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise at 55% of maximum power output for 30 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise at 55% of maximum power output for 30 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: Rest for 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delay
Description: Delay between exercise and OGTT
Study: NCT01636973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaporizing humidifier
Description: Vaporizing humidifier applying during one-lung ventilation
Study: NCT04327765

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.5mg AZ-010
Description: Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1mg AZ-010
Description: Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3mg AZ-010
Description: Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
Study: NCT00069927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-XR®
Description: Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-XR®
Description: Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concerta®
Description: Concerta® 18 mg/day for 3-12 weeks depending on subject's response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concerta®
Description: Concerta® 18 mg/day for 3-12 weeks depending on subject's response
Study: NCT02013947

Intervention type: OTHER
Group type: OTHER
Intervention: 2 weeks of exercise in low and moderate altitude
Description: Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).

Intervention type: OTHER
Group type: OTHER
Intervention: 2 weeks of exercise in low and moderate altitude
Description: Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).
Study: NCT01414699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Variety
Description: These conditions will have snack served with an increase of fruit variety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Variety
Description: These conditions will have snack served with an increase of fruit variety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Variety
Description: These conditions will receive a snack without a variety of fruit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Variety
Description: These conditions will receive a snack without a variety of fruit.
Study: NCT04154670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be given intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be given intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be given intravenously
Study: NCT02227628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acai polyphenolics
Description: Acai beverage was obtained from the Sambazon (San Clemente, CA).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugary Beverage
Description: An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD\&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
Study: NCT03789942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral surgery
Description: Oral surgery procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral surgery
Description: Oral surgery procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral surgery
Description: Oral surgery procedures
Study: NCT03210389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
Study: NCT04452045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SweetDreams
Description: SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
Study: NCT00625989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aeroallergen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aeroallergen
Study: NCT00054704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03039400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided home exercise with web-based support
Description: Those in the web-based physio group will access their exercise program online and will be able to leave messages for their physiotherapist on the platform. Physiotherapists will monitor usage and respond to messages every two weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapist-guided home exercise with standard support
Description: Those in the standard care group will receive a written, home-based exercise program. Participants in the usual care group will be asked to keep an exercise diary, in paper format.
Study: NCT00124059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: 400mg/day quetiapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: 400mg/day quetiapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg/day placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg/day placebo
Study: NCT00792194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day.
Study: NCT03527134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
Study: NCT01979159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Description: Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
Study: NCT01645189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hunterase
Description: once weekly, 0.5mg/kg IV infusion
Study: NCT00906802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R-Y reconstruction
Description: The reconstruction was performed by R-Y anastomosis.
Study: NCT04272671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.
Study: NCT03118700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Exercise
Description: Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise
Description: Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
Study: NCT01543152

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
Study: NCT02687542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 low dose (1 mg QD)
Description: PF-06649751 low dose (1 mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 middle dose 1 (3 mg QD)
Description: PF-06649751 lower middle dose 1 (3 mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 middle dose 2 (7 mg QD)
Description: PF-06649751higher middle dose 2 (7 mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 high dose (15 mg QD)
Description: PF-06649751 high dose (15 mg QD)
Study: NCT00612950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon-like peptide-1,
Description: GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose dependent insulinotropic polypeptide
Description: continuous infusion of GIP (1½ pmol/kg/min) for 120 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: continuous infusion of Saline for 120 min
Study: NCT04552275

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Proteomics Analysis
Description: Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Proteomics Analysis
Description: Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)
Study: NCT02140697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hippophae rhamnoides L. Leaf Extract (3g/day)
Description: Hippophae rhamnoides L. Leaf extract (3g/day), parallel design

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (3g/day)
Description: Placebo (3g/day), parallel design
Study: NCT01756534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL
Description: Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
Study: NCT01534312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGMP protein
Description: Casein glycomacropeptide purified powder dissolved in 300 ML water once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maximal oral 5ASA
Description: 4800 grams/day of Mesalazine (Asacol/Mezavant)
Study: NCT02999542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Children will be randomised to receive either music via headphones or silence via headphones

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No music
Description: Children will be randomised to receive either music via headphones or silence via headphones
Study: NCT04411485

Intervention type: OTHER
Intervention: Sexual dysfunction
Description: Sexual dysfunction will be determined with separate scales for women and men

Intervention type: OTHER
Intervention: Sexual dysfunction
Description: Sexual dysfunction will be determined with separate scales for women and men
Study: NCT04660461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30mg
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30mg
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
Study: NCT02345954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Supracervical Hysterectomy and Sacropexy
Description: Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hysteropexy
Description: Laparoscopic hysteropexy
Study: NCT04167046

Intervention type: PROCEDURE
Intervention: Erector spinae block
Description: Preoperative erector spinae block.
Study: NCT01136135

Intervention type: OTHER
Intervention: CARDIAC MRI
Description: To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
Study: NCT01607736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Gait Training
Description: The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
Study: NCT02713542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACP
Description: Autologous Conditioned Plasma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
Study: NCT01868256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early discharge (<72 h)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional discharge
Study: NCT04266262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Description: Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity resistance training (HIRT)
Description: Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary.